We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.
- Authors
Farrar, J T; Cleary, J; Rauck, R; Busch, M; Nordbrock, E
- Abstract
Patients with cancer frequently experience episodes of acute pain, i.e., breakthrough pain, superimposed on their chronic pain. Breakthrough pain is usually treated with short-acting oral opioids, most of which provide some relief after 15-20 minutes, with peak effects after 30-45 minutes. Oral transmucosal fentanyl citrate (OTFC), a unique formulation of the opioid fentanyl, has been shown to provide meaningful pain relief within 5 minutes in patients following surgery. We conducted a multicenter, randomized, double-blinded, placebo-controlled trial of OTFC for cancer-related breakthrough pain.
- Publication
Journal of the National Cancer Institute, 1998, Vol 90, Issue 8, p611
- ISSN
0027-8874
- Publication type
Journal Article
- DOI
10.1093/jnci/90.8.611